Puerperal disorder
diseaseOn this page
Also known as disorder of puerperiumdisorder, puerperaldisorders, puerperal
Summary
Puerperal disorder (MONDO:0044013) is a disease with 1 GWAS associations across 3 studies and 6 clinical trials. Top therapeutic interventions include ferric carboxymaltose, ferrous sulfate, and ganaxolone. A subtype of obstetric disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | puerperal disorder |
| Mondo ID | MONDO:0044013 |
| EFO | EFO:0009683 |
| MeSH | D011644 |
| SNOMED CT | 362973001 |
| UMLS | C0034040 |
| MedGen | 18758 |
| Is cancer (heuristic) | no |
Also known as: disorder of puerperium · disorder, puerperal · disorders, puerperal · puerperal disorder
Data availability: 1 GWAS association (3 studies).
Disease family
This is a subtype of obstetric disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › obstetric disorder › puerperal disorder
Related subtypes (1): pregnancy disorder
Subtypes (4): postpartum psychosis, puerperal infection, postpartum amenorrhea-galactorrhea syndrome, postpartum thyroiditis
Genetics & variants
GWAS landscape
1 GWAS associations across 3 studies. Top hits map to 1 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs373736595 | 1e-09 | TNRC6B | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90651308 | Liu TY | 2025 | 328 | 128,981 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90436566 | Zhou W | 2018 | 262 | 408,481 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90727221 | Kim HI | 2026 | 230 | 43,796 | Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs373736595 | 22 | 40065163 | A>G | intron_variant | TNRC6B | 1e-09 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 2 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00660933 | PHASE4 | COMPLETED | Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia |
| NCT00929409 | PHASE2/PHASE3 | TERMINATED | Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia |
| NCT04222348 | PHASE3 | UNKNOWN | MeDiGes Study: Metformine Use in Gestational Diabetes |
| NCT03228394 | PHASE2 | COMPLETED | A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression |
| NCT02664467 | Not specified | COMPLETED | Chronobiology, Sleep Related Risk Factors and Light Therapy in Perinatal Depression: the Life-ON Project |
| NCT06664593 | Not specified | COMPLETED | Screening for Depression and Anxiety in Pregnant and Postpartum Women: Evaluating Prevalence, Risk Factors, and the Stepped Screening Protocol in a Care Pathway |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FERRIC CARBOXYMALTOSE | 4 | 1 |
| FERROUS SULFATE | 4 | 1 |
| GANAXOLONE | 4 | 1 |
| INSULIN DETEMIR | 4 | 1 |
| IRON SUCROSE | 4 | 1 |
| SODIUM CHLORIDE | 4 | 1 |